Ambiguous findings concerning potential advantages of depot antipsychotics: In search of clinical relevance

Current Opinion in Psychiatry

Volumn 28, Issue 3, 2015, Pages 216-221

  Haddad, Peter M ^a,b   Kishimoto, Taishiro ^c,d,e,f   Correll, Christoph U ^d,e,f,g   Kane, John M ^d,e,f,g  

^a GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

antipsychotic long acting injection; depot; effectiveness; schizophrenia

Indexed keywords

ARIPIPRAZOLE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE; ZUCLOPENTHIXOL; DELAYED RELEASE FORMULATION;

COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; HUMAN; INJECTION; LONG ACTING INJECTION; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; STUDY DESIGN; TREATMENT FAILURE; DELAYED RELEASE FORMULATION; METHODOLOGY; SCHIZOPHRENIA; STATISTICAL BIAS;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCHIZOPHRENIA;

EID: 84926379869     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000160     Document Type: Review

References (20)

1. Haddad PM, Brain C, Scott J. A review of nonadherence to antipsychotic medication in schizophrenia; challenges and management strategies. Patient Relat Outcome Meas 2014; 5: 43-62
2. Patel MX, Haddad PM, Chaudhry IB, et al. Psychiatrists' use, knowledge and attitudes to first-and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473-1482.
3. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009; 52: S37-S42.
4. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568-575.
5. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013; 40: 192-213.
6. Schreiner A, Adamsoo K, Altamura AC et al. A randomised, active-controlled rated-blinded 2-year study of paliperidone palmitate versus investigators' choice of oral antipsychotic monotherapy in patients with schizophrenia (PROSIPAL). Poster presented at CINP. Canada: Vancouver; 22-26 June 2014. Poster LP-01-013.
7. Starr HL, Mao L, Lindmayer J-P et al. Paliperidone palmitate research in demonstrating Effectiveness (PRIDE): managing schizophrenia patients with a history of incarceration and substance abuse. Poster presented at American Psychiatric Association (APA) 167th Annual Meeting. New York, NY, USA; 3-7 May 2014. Poster NR8-150.
8. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013; 74: 957-965.
9. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 2014; 311: 1978-1987.
10. Fleischhacker WW. Antipsychotic medications for schizophrenia. Comment on: Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 2014; 312: 1467-1468.
11. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, noninferiority study. Br J Psychiatry 2014; 205: 135-144.
12. Ishigooka J, Nakamura J, Fujii Y, et al., ALPHA Study Group. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, noninferiority study versus oral aripiprazole. Schizophr Res 2015; 161 (2-3): 421-428.
13. Buckley PF, Schooler NR, Goff DC, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull 2015; 41: 449-459.
14. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al., CGS Study Group. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012; 134 (2-3): 187-194.
15. Novick D, Haro JM, Bertsch J, et al. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications. Int Clin Psychopharmacol 2012; 27: 275-282.
16. Bitter I, Katona L, Zámbori J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013; 23: 1383-1390.
17. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-609.
18. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962.
19. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 2013; 66 (8 Suppl): S37-S41.
20. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58: 482-488.